- Home
- DYN vs CLDX Comparison
DYN vs CLDX Comparison
Compare DYN & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- CLDX
- Stock Information
- Founded
- DYN 1984
- CLDX N/A
- Country
- DYN United States
- CLDX United States
- Employees
- DYN N/A
- CLDX N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DYN Health Care
- CLDX Health Care
- Exchange
- DYN Nasdaq
- CLDX Nasdaq
- Market Cap
- DYN 1.9B
- CLDX 1.9B
- IPO Year
- DYN 2020
- CLDX 2008
- Fundamental
- Price
- DYN $22.76
- CLDX $26.11
- Analyst Decision
- DYN Strong Buy
- CLDX Buy
- Analyst Count
- DYN 14
- CLDX 10
- Target Price
- DYN $34.93
- CLDX $44.20
- AVG Volume (30 Days)
- DYN 2.9M
- CLDX 810.0K
- Earning Date
- DYN 10-28-2025
- CLDX 11-03-2025
- Dividend Yield
- DYN N/A
- CLDX N/A
- EPS Growth
- DYN N/A
- CLDX N/A
- EPS
- DYN N/A
- CLDX N/A
- Revenue
- DYN N/A
- CLDX $5,790,000.00
- Revenue This Year
- DYN N/A
- CLDX N/A
- Revenue Next Year
- DYN N/A
- CLDX N/A
- P/E Ratio
- DYN N/A
- CLDX N/A
- Revenue Growth
- DYN N/A
- CLDX N/A
- 52 Week Low
- DYN $6.36
- CLDX $14.40
- 52 Week High
- DYN $35.68
- CLDX $29.05
- Technical
- Relative Strength Index (RSI)
- DYN 74.02
- CLDX 48.64
- Support Level
- DYN $23.05
- CLDX $25.70
- Resistance Level
- DYN $25.00
- CLDX $27.85
- Average True Range (ATR)
- DYN 1.00
- CLDX 1.12
- MACD
- DYN 0.72
- CLDX -0.24
- Stochastic Oscillator
- DYN 78.19
- CLDX 11.72
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.